It was interesting to note that the dose-dependent loss of proliferative capacity due to HVS treatment positively correlates with the level of c-Met expression in different human breast cancer cells, supporting the hypothesis that c-Met inhibition can be the mechanism for the antitumor effects of this oleocanthal-based derivative. This evidence concerns the gene MET and breast carcinoma.